KLRS 株価推移チャート
KLRS 収入
Kalaris Therapeutics Inc
$4.73
-6.88%
$-0.34
終値： May 11, 16:00:00 GMT-4
$4.82
1.9%
$0.08
アフターマーケット：May 11, 20:00:00 GMT-4
戻る
Kalaris Therapeutics Inc (KLRS) 収入
主要データ
前終値
$5.08
始値
$5.02
当日レンジ
$4.69 - $5.05
52週レンジ
$2.14 - $11.88
取引高
155.0K
平均取引高
74.5K
配当利回り
--
1株当たり利益(TTM)
-4.27
時価総額
$110.5M
KLRSとは何ですか？
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. The company is headquartered in Berkeley Heights, New Jersey and currently employs 20 full-time employees. The company went IPO on 2020-07-30. The firm is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
